Literature DB >> 9662125

Insulin-like growth factor-I and bone mineral density.

D Collins1, A Woods, R Herd, G Blake, I Fogelman, M Wheeler, R Swaminathan.   

Abstract

To assess the relationship between insulin-like growth factor-I (IGF-I) and bone mineral density (BMD) 201 healthy postmenopausal women (age 41-68 years) within 10 years of menopause were studied. In all subjects, BMD at the lumbar spine and left hip were measured using dual-energy X-ray absorptiometry and blood samples were obtained. In all subjects, serum IGF-I and parathyroid hormone (PTH) were measured. In a subgroup of these subjects serum concentrations of IGF-binding protein-3 (IGFBP-3), osteocalcin (OC), bone-specific alkaline phosphatase (BALP), tartrate-resistant acid phosphatase (TRAP), and carboxyterminal propeptide of type I procollagen (PICP) were also measured. Serum IGF-I correlated significantly with age (r = -0.159, p = 0.0241), serum OC (r = 0.226, p = 0.0131), BALP (r = 0.259, p < 0.0001), and TRAP (r = 0.261, p < 0.0015), but not with PICP, PTH, or BMD at any site. Although there was a strong correlation between IGF-I and IGFBP-3 (r = 0.559, p < 0.0001), there was no correlation between IGFBP-3 and any of the markers of bone turnover (OC, BALP, TRAP, or PICP) nor with PTH or BMD at any site. We conclude that IGF-I and markers of bone turnover are related, but there is no relationship between IGF-I and BMD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9662125     DOI: 10.1016/s8756-3282(98)00066-0

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

1.  Evaluation of bone mineral density loss in morbidly obese women after gastric bypass: 3-year follow-up.

Authors:  Nuria Vilarrasa; Patricia San José; Isabel García; Carmen Gómez-Vaquero; Pilar Medina Miras; Amador G Ruiz de Gordejuela; Carles Masdevall; Jordi Pujol; Joan Soler; José Manuel Gómez
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

2.  Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.

Authors:  T Yamaguchi; M Kanatani; M Yamauchi; H Kaji; T Sugishita; D J Baylink; S Mohan; K Chihara; T Sugimoto
Journal:  Calcif Tissue Int       Date:  2006-01-06       Impact factor: 4.333

3.  IGF-1 and survival in ESRD.

Authors:  Ting Jia; Thiane Gama Axelsson; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel; Abdul Rashid Qureshi
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

4.  Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.

Authors:  Adrian G Ruetsche; Renato Kneubuehl; Martin H Birkhaeuser; Kurt Lippuner
Journal:  Osteoporos Int       Date:  2004-10-16       Impact factor: 4.507

5.  Influence of polymorphisms in insulin-like growth factor-1 on the risk of osteoporosis in a Chinese postmenopausal female population.

Authors:  Feng Li; Wen-Hua Xing; Xue-Jun Yang; Hai-Yan Jiang; Hong Xia
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Effect of low-intensity aerobic exercise on insulin-like growth factor-I and insulin-like growth factor-binding proteins in healthy men.

Authors:  Yuichiro Nishida; Takeshi Matsubara; Takuro Tobina; Munehiro Shindo; Kumpei Tokuyama; Keitaro Tanaka; Hiroaki Tanaka
Journal:  Int J Endocrinol       Date:  2010-09-22       Impact factor: 3.257

7.  Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.

Authors:  R Torrisi; L Baglietto; H Johansson; G Veronesi; B Bonanni; A Guerrieri-Gonzaga; B Ballardini; A Decensi
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

8.  The polymorphism of Insulin-like growth factor-I (IGF-I) is related to osteoporosis and bone mineral density in postmenopausal population.

Authors:  Li Yun-Kai; Wang Hui; Zhu Xin-Wei; Guo Liang; Zuo Jin-Liang
Journal:  Pak J Med Sci       Date:  2014-01       Impact factor: 1.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.